2nd Peptide-Based Therapeutics Summit

With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular space, peptide therapeutics are firmly back on the map as the next modality disrupting drug discovery and development.

Join us at the 2nd Peptide-Based Therapeutics Summit, where we’ll unite the leading minds in peptide science to explore the latest advancements driving the next wave of peptide-based therapies—from early-stage discovery to clinical application.

This year’s summit will focus on cutting-edge innovations in peptide therapeutics, including:

• Peptide 3D structure prediction, hit generation, and lead optimization with Chugai Pharmaceutical, PeptiDream, and Insamo
• Optimizing oral bioavailability and cell permeability in peptide design, with insights from Orbis Medicines and Ohio State University
• Formulating peptides for optimal target binding, solubility, stability, and safety with Halozyme and Oramed Pharmaceuticals

Curious? Download the official brochure here.

Special Offer: Save up to 20% when you register with colleagues!